, NGS : Next generation Sequencing) qui permet de comparer et d'analyser les ARN viraux des différents sous-types
, Tableau 8 : détail de l'organisation des zones à haut risque et à bas risque ainsi que les espaces de passage d'une zone à l'autre
, chief Bernard N. Fields
XIX-2336-83 p.); ill. 29 cm, vol.2, 1990. ,
, Les fièvres hémorragiques à virus Ebola et Marburg : l'actualité des filovirus, 2011.
, , 1947.
); ill. en noir et en coul., jaquette ill.; 31 cm; rel, vol.1, 2003. ,
, , 2007.
Virologie médicale / A. Mammette ,
, ); ill. 24 cm; br. (Collection Azay (Lyon)), vol.1, 2002.
,
Human Infection Due to Ebola Virus, J Infect Dis. 1 févr, vol.179, issue.Supplement_1, pp.48-53, 1999. ,
,
XXI-265 p.); ill.cartes, tabl.graph., couv. ill. en coul.; 25 cm; br. (Abrégés. Connaissances et pratique), vol.1, 2009. ,
, Ebola Virus Disease Distribution Map | Ebola Hemorrhagic Fever | CDC, 2017.
, Outbreaks Chronology: Ebola Virus Disease | Ebola Hemorrhagic Fever | CDC, 2017.
, Médecine & Armées tome, vol.44, issue.2
,
Discovery of an Ebolavirus-Like Filovirus in Europe, PLOS Pathog, vol.7, issue.10, p.1002304, 2011. ,
Mapping the zoonotic niche of Ebola virus disease in Africa, eLife. 8 sept, vol.3, p.4395, 2014. ,
Ebola virus-epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans-an update on its 40 year's journey, Vet Q. déc, vol.37, issue.1, pp.98-135, 2017. ,
XII-284 p.); ill. en noir et en coul., couv. ill. en coul.; 26 cm; br. (Collection De la biologie à la clinique), vol.1, 1921. ,
The lifecycle of the Ebola virus in host cells, Oncotarget. 15 juin, vol.8, issue.33, pp.55750-55759, 2017. ,
, L entrée du virus Ébola et Marburg : interaction entre la glycoprotéine virale et les facteurs cellulaires-PDF
,
, , 2015.
,
, Virus Pathogen Database and Analysis Resource (ViPR)-Filoviridae-Genome database with visualization and analysis tools
Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus, Nat Rev Microbiol, vol.13, issue.11, pp.663-76, 2015. ,
, Virus Ecology | Ebola Hemorrhagic Fever | CDC
, OMS | Ce que l'on sait à propos de la transmission interhumaine du virus Ebola
, 23. francaise C-R. Guide opérationnel sur la lutte contre Ebola
,
,
,
, Les filovirus. Virologie. 1 mars, vol.11, issue.2, pp.105-125, 2007.
Camouflage and Misdirection: The Full-On Assault of Ebola Virus Disease, Cell, vol.159, issue.3, pp.477-86, 2014. ,
, OMS | Définitions de cas recommandées pour la surveillance des maladies à virus Ebola ou Marburg, p.14, 2017.
, OMS | Définitions de cas recommandées pour la surveillance des maladies à virus Ebola ou Marburg, p.14, 2017.
, , p.12, 2017.
,
Development and Evaluation of Reverse Transcription-Loop-Mediated Isothermal Amplification (RT-LAMP) Assay Coupled with a Portable Device for Rapid Diagnosis of Ebola Virus Disease in Guinea, PLoS Negl Trop Dis, vol.22, issue.2016, p.14, 2017. ,
, Swift Analytical | Instruments | Low Volume Liquid Handling and Quantification | DNA, RNA & Proteins
Anses relatif à une « demande d'expertise sur le rôle potentiel des animaux domestiques dans la transmission du virus de la maladie d'Ebola» ,
,
ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study, Lancet Lond Engl. 29 août, vol.386, issue.9996, pp.867-74, 2015. ,
, Ebola : vers un test de diagnostic fiable et rapide [Internet]. lesechos.fr
Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Eurosurveillance. 26 mars, vol.20, issue.12, p.21073, 2015. ,
Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection, J Infect Dis, vol.214, issue.3, pp.203-212, 2016. ,
Validation technique d'un test de diagnostic du virus Ebola en moins de quinze minutes sur le terrain ,
, , 2014.
Validation sur le terrain du nouveau test de diagnostic rapide Ebola eZYSCREEN®Field assessment of the new rapid diagnostic test Ebola eZYSCREEN®, Bull Société Pathol Exot. 1 févr, vol.110, issue.1, pp.38-48, 2017. ,
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus ,
, Antiviral Res, vol.28, issue.2017
,
Favipiravir (T705), a novel viral RNA polymerase inhibitor, Antiviral Res, vol.100, issue.2, 2013. ,
DOI : 10.1016/j.antiviral.2013.09.015
URL : http://europepmc.org/articles/pmc3880838?pdf=render
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res. 1 mai, vol.105, pp.17-21, 2014. ,
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med, vol.13, issue.3, p.16, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01327168
BCX4430-a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease, J Infect Public Health, vol.9, issue.3, pp.220-226, 2016. ,
Protection against filovirus disease by a novel broad-spectrum nucleoside analogue BCX4430, 2014. ,
The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus, Antiviral Res. 1 janv, vol.125, pp.71-79, 2016. ,
Experimental Treatment of Ebola Virus Disease with Brincidofovir, PLOS ONE. 9 sept, vol.11, issue.9, p.162199, 2016. ,
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies, J Virol. 26 août, vol.89, issue.21, pp.10982-92, 2015. ,
Fighting Ebola with ZMapp: spotlight on plant-made antibody, Sci China Life Sci, vol.57, issue.10, pp.987-995, 2014. ,
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp TM, Nature, vol.514, issue.7520, pp.47-53, 2014. ,
Controlled Trial of ZMapp for Ebola Virus Infection, N Engl J Med, vol.375, issue.15, pp.1448-56, 2016. ,
Salle de presse | Inserm, résultats encourageants pour l'essai clinique Prévail, 2016. ,
Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates, Nature. 21 mai, vol.521, issue.7552, pp.362-367, 2015. ,
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial, PLOS Med. 19 avr, vol.13, issue.4, p.1001997, 2016. ,
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments, Nanomaterials. 5 avr, vol.7, issue.4, p.77, 2017. ,
Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, vol.4, pp.2806-2836, 2012. ,
Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies, Antimicrob Agents Chemother, vol.58, issue.11, pp.6639-6686, 2014. ,
Advanced antisense therapies for postexposure protection against lethal filovirus infections, Nat Med. 1 sept, vol.16, pp.991-995, 2010. ,
, AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Disease, ECRI Institute, vol.6002
Interferon ?-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-ofconcept trial, PLoS ONE, vol.22, issue.2017, p.15, 2017. ,
Les différents interférons : Pharmacologie, mécanismes d'action, tolérance et effets secondaires, Rev Médecine Interne, vol.23, pp.449-458, 2002. ,
Interferon-? Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever, J Infect Dis. 15 juill, vol.208, issue.2, pp.310-318, 2013. ,
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet. 13 déc, vol.362, issue.9400, pp.1953-1961, 2003. ,
Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor, J Intern Med, vol.254, issue.4, pp.313-334, 2003. ,
DOI : 10.1046/j.1365-2796.2003.01224.x
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2796.2003.01224.x
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med. 7 janv, vol.374, issue.1, pp.33-42, 2016. ,
Clinical development of Ebola vaccines, Ther Adv Vaccines. sept, vol.3, issue.5-6, pp.125-163, 2015. ,
DOI : 10.1177/2051013615611017
URL : http://journals.sagepub.com/doi/pdf/10.1177/2051013615611017
An Ebola whole-virus vaccine is protective in nonhuman primates, Science. 24 avr, vol.348, issue.6233, pp.439-481, 2015. ,
DOI : 10.1126/science.aaa4919
URL : http://europepmc.org/articles/pmc4565490?pdf=render
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet. 29 août, vol.386, issue.9996, pp.857-66, 2015. ,
, Préparation contre le risque de nouvelles épidémies d'Ebola : la garantie d'achat de vaccin par Gavi
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles, J Virol, vol.12, issue.2017, p.91 ,
DOI : 10.1128/jvi.00343-17
URL : https://jvi.asm.org/content/jvi/91/11/e00343-17.full.pdf
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebocontrolled, phase 2 trial. The Lancet. 11 févr, vol.389, pp.621-629, 2017. ,
Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial, JAMA. 19 avr, vol.315, issue.15, pp.1610-1633, 2016. ,
DOI : 10.1001/jama.2016.4218
URL : https://jamanetwork.com/journals/jama/articlepdf/2514196/jpc160004.pdf
Use of ChAd3EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebocontrolled trial, Lancet Infect Dis. janv, vol.16, issue.1, pp.31-42, 2016. ,
Chimpanzee Adenovirus Vector Ebola Vaccine, N Engl J Med. 9 mars, vol.376, issue.10, pp.928-966, 2017. ,
DOI : 10.1056/nejmoa1410863
URL : http://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep_10Jun2016_eng.pdf?ua=1
, OMS | Les origines de l'épidémie d'Ebola, 2014.
,
Emergence of Zaire Ebola Virus Disease in Guinea, N Engl J Med, vol.371, issue.15, pp.1418-1443, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01011799
, OMS | Les facteurs qui ont contribué à la propagation cachée du virus Ebola et empêché son confinement rapide
, le virus Ebola montre sa ténacité
,
Libéria: un pays, et sa capitale, submergés par les cas d'Ebola ,
une flambée initialement modérée qui s'est finalement révélée être la plus fulgurante ,
Update: Épidémie de maladie à virus Ébola-Afrique de l'Ouest, octobre, 2014. ,
, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic. MMWR Suppl, 2016.
,
, Ebola: géographie, chiffres et histoire de l'épidémie-RFI
, OMS | Feuille de route pour la riposte au virus Ebola: rapports de situation
, Frontières (MSF) MS. Centre de traitement d'Ebola [MSF] by Médecins Sans Frontières (MSF), vol.91
Caisse des Français de l'Etranger ,
,
,